LL-37 and Sepsis Research: Antimicrobial Peptide Biology, Endotoxin Neutralisation and Systemic Infection Mechanisms UK 2026

This article is intended for researchers and laboratory professionals. All peptides discussed are for research use only (RUO) and are not approved for human administration, therapeutic use, or clinical application. PeptidesLab UK supplies research-grade LL-37 for in vitro and in vivo laboratory investigations only.

LL-37 in Sepsis Biology: Cathelicidin at the Innate Immune–Endotoxin Interface

LL-37, the sole human cathelicidin processed from hCAP18 (human cationic antimicrobial protein 18 kDa) by proteinase 3 at the Ala-Leu bond, has emerged as a central participant in the host response to systemic bacterial infection. In sepsis research, LL-37’s biological significance extends well beyond direct antimicrobial activity: the peptide binds and neutralises lipopolysaccharide (LPS, endotoxin) from Gram-negative bacteria, lipoteichoic acid (LTA) from Gram-positive organisms, and the danger-associated molecular pattern (DAMP) HMGB1 — each critically implicated in the dysregulated inflammatory cascade that drives septic organ dysfunction. Understanding LL-37’s multifaceted roles in sepsis models provides mechanistic insight into innate immune regulation during life-threatening systemic infection.

Circulating LL-37 in healthy humans ranges from ~0.5-3 μg/mL in plasma, primarily stored in neutrophil secondary granules as hCAP18 (cleaved upon degranulation by proteinase 3) and in epithelial secretions. In septic patients, plasma LL-37 levels are paradoxically reduced compared to healthy controls in some studies (attributed to consumption, protease degradation, and neutrophil exhaustion), while local tissue concentrations may be substantially elevated at sites of infection. This “LL-37 paradox” in sepsis — insufficient systemic levels despite ongoing infection — provides the research rationale for exogenous supplementation studies in preclinical models.

LPS Binding and Endotoxin Neutralisation: Biophysical Mechanisms

LL-37’s endotoxin-neutralising capacity derives from direct electrostatic and hydrophobic interactions with the lipid A moiety of LPS — the toxic component responsible for TLR4 activation and cytokine storm initiation. Biophysical characterisation using isothermal titration calorimetry (ITC, MicroCal PEAQ-ITC) demonstrates that LL-37 binds E. coli O111:B4 LPS with Kd ~0.1-1 μM, driven by both electrostatic (cationic LL-37 + anionic phosphate groups of lipid A) and hydrophobic (helical face insertion into acyl chains) contributions. Dynamic light scattering (DLS) and zeta potential measurements show that LL-37 disaggregates LPS micelles (reducing particle size from >100 nm to <10 nm aggregates) and reverses surface charge from negative to neutral-positive, directly impairing TLR4/MD-2 recognition.

The standard LPS neutralisation assay for research validation employs the limulus amebocyte lysate (LAL) test in kinetic turbidimetric format (Charles River Endosafe PTS or Lonza PyroGene): pre-incubating LPS (1-10 EU/mL E. coli O111:B4) with increasing LL-37 concentrations (0.1-100 μg/mL) before LAL challenge demonstrates concentration-dependent endotoxin neutralisation, with IC50 typically 5-20 μg/mL. Functional TLR4 neutralisation is confirmed in TLR4-expressing HEK293 reporter cells (HEK-Blue hTLR4, InvivoGen) — LL-37 pre-incubation with LPS dose-dependently reduces SEAP (secreted alkaline phosphatase) reporter activity, with 80-90% inhibition at 10-20 μg/mL. FRET-based assays using dye-labelled LPS and LL-37 confirm direct molecular interaction kinetics in solution.

CLP Model of Polymicrobial Sepsis: Experimental Design and Endpoints

The caecal ligation and puncture (CLP) model remains the gold standard preclinical model of polymicrobial sepsis, producing bacteraemia with a cytokine profile and organ dysfunction pattern closely paralleling human sepsis. In C57BL/6 mice (8-12 weeks, 20-25g), CLP is performed under isoflurane anaesthesia: the caecum is exposed, ligated 50% of its length (below the ileo-caecal junction), and punctured through-and-through with a 22g needle (1 puncture = moderate sepsis, 2 punctures = severe sepsis). Faecal content expressed from the puncture site creates a peritoneal nidus of polymicrobial infection dominated by Enterobacteriaceae, Bacteroidetes, Enterococcus species, and anaerobes. Immediate post-operative fluid resuscitation (1 mL warm saline s.c.) standardises the model.

LL-37 treatment protocols in CLP research include: (i) prophylactic — LL-37 administered 1h pre-CLP (i.p. or i.v., 5-20 mg/kg); (ii) early therapeutic — administered at time of CLP or within 1-2h post; (iii) delayed therapeutic — 6h post-CLP, matching clinical scenarios of late presentation; (iv) combination — LL-37 + standard-of-care antibiotics (imipenem 25 mg/kg, meropenem, or levofloxacin). Primary endpoints: 7-day survival (Kaplan-Meier, log-rank test); secondary endpoints: bacterial load in peritoneal lavage fluid (25 mL PBS, plating on blood agar and MacConkey, CFU/mL at 18-24h post-CLP), blood culture (aerobic and anaerobic, 100 μL via cardiac puncture), and organ function biomarkers (plasma creatinine, BUN for kidney; ALT/AST for liver; troponin for heart; PaO₂:FiO₂ ratio for lung).

Cytokine Storm Modulation: TLR4-NF-κB and HMGB1 Pathways

Septic cytokine dysregulation involves both early mediators (TNF-α, IL-1β, IL-6, IL-12, IFN-γ — peak 2-6h post-LPS) and late mediators (HMGB1 — peak 18-32h post-LPS or CLP, critical for lethality). LL-37 modulates both phases. For early cytokine research: LPS-stimulated macrophage cultures (THP-1 PMA-differentiated, primary BMDM from CLP-model mice, peritoneal macrophages isolated by lavage) treated with LL-37 (1-20 μg/mL) ± LPS (100 ng/mL, E. coli O111:B4) assess NF-κB p65 nuclear translocation by confocal immunofluorescence (anti-p65, Cell Signaling 8242; DAPI nuclear co-stain; ImageJ nuclear:cytoplasmic ratio), IκBα Ser-32 phosphorylation by Western (Cell Signaling 2859), and cytokine output by Luminex multiplex (TNF-α, IL-1β, IL-6, IL-10, IL-12p70, MIP-1α) in conditioned media at 4, 8, and 24h.

HMGB1 research in sepsis models focuses on LL-37’s capacity to neutralise extracellular HMGB1 — a late-phase DAMP released by activated macrophages, damaged cells, and neutrophil NETs that perpetuates inflammation through RAGE, TLR4, and TLR2. LL-37 binds HMGB1 with Kd ~50-200 nM (SPR, Biacore), blocking HMGB1-RAGE interaction confirmed by competitive ELISA (biotinylated HMGB1 + RAGE-Fc in the presence of LL-37 titration). In CLP mice at 20-24h — the peak of HMGB1 release — plasma HMGB1 (ELISA, IBL International) is significantly elevated versus sham; LL-37 treatment initiated at 12h post-CLP (i.e., after the early cytokine peak) reduces plasma HMGB1 at 24h and improves 7-day survival in moderate CLP, demonstrating therapeutic efficacy in the clinically challenging late-phase window.

Neutrophil Biology in Sepsis: NETosis, Priming, and LL-37 Paradox

Neutrophil-derived LL-37 exerts autocrine and paracrine effects central to sepsis biology. Upon neutrophil activation (fMLP, LPS, C5a, IL-8), hCAP18-containing secondary granules fuse with the plasma membrane, releasing hCAP18 into the extracellular space where proteinase 3 (also neutrophil-derived) cleaves it to active LL-37. LL-37 then acts as a neutrophil chemokine (FPR2/FPRL1 receptor, Gi signalling) creating an autocrine amplification loop. Research using isolated human neutrophils (Ficoll-Hypaque gradient, ≥95% purity by Diff-Quik) assesses: intracellular hCAP18/LL-37 by intracellular flow cytometry (anti-LL-37 antibody, Hycult HM2070, after fix/perm with BD Cytofix/Cytoperm); degranulation by CD63/CD66b surface upregulation (flow, 15 min stimulation); and extracellular LL-37 ELISA (Hycult HK321) in supernatants.

NETosis (neutrophil extracellular trap formation) is strongly induced by LPS and is regulated by LL-37. NETs — chromatin decorated with neutrophil elastase, MPO, citrullinated histone H3 — trap and kill bacteria but also amplify inflammation and activate platelets (contributing to DIC). LL-37 stimulates NETosis via FPR2 (confirmed by WRW4 FPR2 antagonist) at concentrations ≥10 μg/mL through a PAD4-citrullination dependent pathway. Paradoxically, LL-37 also accelerates NET degradation by acting as an opsonin for DNase I and by reducing excessive NET-platelet interactions. Research quantifying NETs uses SYTOX Green fluorescence (intact cell-impermeable, NET-specific, 485/523 nm, plate reader) or confocal imaging for citrullinated H3 (Cit-H3, Abcam ab5103) + MPO (Dako A0398) + extracellular DNA (DAPI) co-localisation. PMA (100 nM, 3h) serves as positive control; DNase I (10 μg/mL, 15 min) confirms NET specificity.

Organ Protection Research: Lung, Kidney, and Liver in Septic Models

Sepsis-induced organ dysfunction is mediated by a combination of direct microbial injury, cytokine-driven endothelial permeability, neutrophil tissue infiltration, mitochondrial dysfunction, and dysregulated coagulation. LL-37 research addresses each of these mechanisms across target organs.

Lung (ALI/ARDS model): Intratracheal LPS (2-5 mg/kg in 50 μL PBS, C57BL/6) produces acute lung injury characterised by increased bronchoalveolar lavage fluid (BALF) protein (BCA assay, g/L), neutrophil count (Diff-Quik cytospin, cells/mL), TNF-α/IL-1β/IL-6/CXCL1 (Luminex), and lung wet:dry weight ratio. Intratracheal LL-37 (0.5-5 mg/kg in 50 μL) co-administration or 1h post-LPS treatment reduces BALF neutrophilia and cytokines, with lung histology (H&E, 5-point ALI score: oedema, hyaline membranes, neutrophil infiltration, haemorrhage, septal thickening) confirming tissue protection. Tight junction proteins (ZO-1, occludin, claudin-5) by Western in lung lysates and permeability assays (Evans Blue dye 20 mg/kg i.v., spectrophotometry at 620 nm, lung homogenate) quantify endothelial barrier protection.

Kidney (AKI model): LPS (10-20 mg/kg i.p.) or CLP-induced AKI assessed by serum creatinine (Jaffe method, Sigma MAK080), BUN (QuantiChrom BUN assay), NGAL (neutrophil gelatinase-associated lipocalin, plasma ELISA — early sensitive AKI biomarker), and KIM-1. Kidney histology scores tubular necrosis, cast formation, and inflammatory infiltration (PAS-stained sections). LL-37 treatment (3-10 mg/kg i.p.) 1h before LPS reduces serum creatinine and BUN at 24h, with mechanistic attribution to TLR4 blockade in proximal tubular epithelial cells (HK-2, RPTEC) confirmed by NF-κB reporter and caspase-3/7 apoptosis assay (Caspase-Glo 3/7, Promega) in vitro.

Liver: LPS-induced hepatic dysfunction model (D-galactosamine sensitisation, 700 mg/kg i.p. + LPS 10 μg/kg — 90% mortality within 8h) provides a stringent survival endpoint. ALT/AST (automated chemistry, IDEXX Catalyst) in plasma at 6h, TUNEL+ hepatocyte apoptosis, and NF-κB p65 nuclear IHC in liver sections characterise hepatic injury. LL-37 (3-10 mg/kg i.p.) 30 min before GalN/LPS challenge significantly improves survival in this model, with mechanistic attribution to LPS neutralisation before TLR4 activation using the LAL assay on plasma collected 15-30 min post-LPS injection.

LPS Structure Specificity: Rough vs Smooth LPS, E. coli vs P. aeruginosa vs K. pneumoniae

LL-37’s LPS-binding and neutralisation capacity varies substantially with LPS structure. Rough LPS (Ra-Re chemotypes — lacking O-antigen polysaccharide) is bound and neutralised more effectively than smooth LPS (S-form — full O-antigen chain), as the O-antigen sterically impedes access to lipid A. E. coli LPS (predominantly hexa-acylated lipid A, strong TLR4 activator) is more potently neutralised by LL-37 than P. aeruginosa LPS (penta-acylated, less potent TLR4 activator), and substantially more than K. pneumoniae LPS which has longer chain acylation patterns. Research systematically comparing LL-37 neutralisation of LPS from clinically relevant Gram-negative sepsis pathogens (E. coli, K. pneumoniae, P. aeruginosa, Acinetobacter baumannii, Haemophilus influenzae) in LAL and THP-1 cytokine release assays provides clinically relevant ranking for research translation.

Gram-positive sepsis models use lipoteichoic acid (LTA, S. aureus) or whole heat-killed bacteria (HKSA, HKSP) as TLR2 stimuli. LL-37 binds S. aureus LTA (Kd ~1-5 μM, ITC) and reduces THP-1 IL-8/TNF-α/IL-6 release in response to HKSA, although less potently than LPS neutralisation, reflecting the differential acyl chain chemistry. Dual Gram-positive/Gram-negative models using polymicrobial CLP bacteria provide research context for LL-37’s broad-spectrum anti-inflammatory activity across pathogen classes.

Immunomodulatory Receptor Signalling: FPR2, P2X7, EGFR and MAPK Pathways

Beyond LPS neutralisation, LL-37 activates immunomodulatory receptor pathways that shape the septic immune response. FPR2 (formyl peptide receptor 2, also termed FPRL1 or ALX) is the primary cellular receptor for LL-37 on neutrophils, monocytes, and epithelial cells, coupling through Gi/o to inhibit cAMP production, activate PI3K-Akt-Rac1, and promote pro-resolution signalling (phagocytosis of apoptotic cells, lipoxin-like effects at higher concentrations). Research using FPR2-deficient macrophages (Fpr2⁻/⁻ C57BL/6) or FPR2 antagonist WRW4 (10 μM) demonstrates that LL-37’s anti-apoptotic effects on macrophages in LPS-challenge are partially FPR2-dependent, while direct LPS neutralisation is FPR2-independent — pharmacologically dissecting receptor-mediated from direct binding mechanisms.

P2X7 receptor (ATP-gated non-selective cation channel on macrophages) activation by extracellular ATP released from damaged septic cells drives NLRP3 inflammasome assembly → caspase-1 activation → IL-1β/IL-18 maturation and gasdermin-D pyroptosis. LL-37 activates P2X7 at high concentrations (>5 μg/mL) via membrane perturbation, potentially amplifying inflammasome activation. This pro-inflammatory receptor interaction of LL-37 is concentration and context-dependent and represents an important caveat for high-dose treatment designs in sepsis research. NLRP3 inflammasome research uses the canonical activation protocol: LPS prime (1 μg/mL, 4h) + ATP challenge (5 mM, 30 min) in THP-1 or BMDM cells, with IL-1β ELISA (R&D DY201), gasdermin-D cleavage (N-terminal fragment, Western, Abcam ab209845), and LDH cytotoxicity assay (Promega) as tri-part endpoint package.

Degradation-Resistant Analogues and Research Tool Compounds

Native LL-37 has a serum half-life of approximately 30-60 minutes owing to proteolytic cleavage by metalloproteinases (MMP-7, elastase, proteinase 3, cathepsin G) at multiple sites, limiting its utility in systemic infection models. Research on LL-37 analogues for improved stability includes: (i) D-amino acid substitution — D-LL-37 (full D-enantiomer) retains LPS-neutralising capacity (chirality-independent electrostatic mechanism) while achieving resistance to all L-specific proteases (t½ extended to >12h in 10% human serum); (ii) truncated analogues — FK-13 (LL-37 residues 17-29), KR-12 (residues 18-29), and LLKKK18 retaining core antimicrobial/endotoxin-binding helical domain in shorter, more metabolically stable formats; (iii) lipidation — N-terminal palmitoylation increases serum stability and membrane affinity while retaining antimicrobial activity; (iv) PEGylation — improving half-life at the cost of some direct antimicrobial potency, trading LPS neutralisation IC50 from ~5 μg/mL to ~20-30 μg/mL for PEGylated constructs.

Comparative stability assays in research: incubation of native LL-37 versus analogues in 10% pooled human serum (37°C, 0-240 min) with HPLC-MS quantification of intact peptide at 30-min intervals generates half-life estimates. LAL functional assay at each time point confirms that endotoxin-neutralising activity parallels intact peptide concentration. D-LL-37 comparison in CLP model (equimolar dosing to native LL-37) directly assesses in vivo relevance of the stability improvement on survival, plasma HMGB1, and organ dysfunction biomarkers.

Control Design and Experimental Rigour in Sepsis Research

Rigorous LL-37 sepsis research requires: (i) endotoxin-free peptide preparation — LL-37 ≥95% purity (RP-HPLC), endotoxin ≤1 EU/mg (LAL test critical — contaminated LL-37 preparations confound all LPS-neutralisation experiments); (ii) vehicle-matched controls — peptide carrier (0.01% acetic acid or PBS at matched pH and osmolality) administered identically; (iii) scrambled peptide (same amino acid composition, randomised sequence, cannot form α-helix) confirms sequence-specific helical structure requirement; (iv) positive controls — polymyxin B (established clinical LPS-neutralising antibiotic) for LPS neutralisation assays; imipenem/cilastatin for CLP survival; recombinant TNF-α blocking antibody for cytokine storm attenuation; (v) sham surgery (identical anaesthesia and laparotomy without CLP) as baseline surgical stress control; (vi) sex-stratified CLP cohorts — female mice show lower mortality than male at equivalent CLP severity due to sex hormone immunomodulation of the septic response, requiring sex-stratified analysis; (vii) clinical severity scoring — murine sepsis score (MSS: coat appearance, eye discharge, breathing, locomotion, response to stimulation — 0-2 each, total 0-10) at 6h intervals post-CLP for welfare and model severity standardisation.